| PRECLINICAL | evidence | Ozempic babies: are weight loss drugs leading to unintended pregnancies? | Ozempic | — | 2025-01-29 |
| PRECLINICAL | evidence | Clinical Data Mega-Collection of Obesity and Obesity-Related Trials: Primary Inclusion Criteria from All Studies and Highlights of Clinical Efficacy Analysis of GLP-1 Drugs. | Wegovy | — | 2025-01-26 |
| PRECLINICAL | evidence | Can weight loss drugs like Ozempic treat obesity in children? | Ozempic | — | 2025-01-23 |
| PRECLINICAL | evidence | The prevalence and consequences of support for off-label Ozempic prescriptions. | Ozempic | — | 2025-01-07 |
| PRECLINICAL | evidence | Longitudinal Analysis of Obesity Drug Use and Public Awareness. | Wegovy | Weight & fat loss | 2025-01-02 |
| PRECLINICAL | evidence | In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder. | Ozempic | Addiction & substance use | 2025-01-01 |
| PRECLINICAL | evidence | Health Beliefs and Obesity Bias as Determinants of Attitudes Toward the Rising Tides of GLP-1 Medications: Mounjaro and Ozempic. | Ozempic | — | 2025-01-01 |
| PRECLINICAL | evidence | Fecal Microbiota Transplantation as an Alternative Method in the Treatment of Obesity. | Ozempic | — | 2025-01-01 |
| PRECLINICAL | evidence | Closing Gaps in Chronic Kidney Disease Detection: Evaluating At-Home Targeted Testing in a Safety-Net Population. | Ozempic | Kidney function | 2025-01-01 |
| PRECLINICAL | evidence | Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023. | Wegovy | — | 2025-01-01 |
| PRECLINICAL | evidence | Hyperdilute Radiesse Preserves Facial Volume in Glucagon-Like Peptide-1 Receptor Agonist Users Undergoing Rapid Weight Loss. | Ozempic | — | 2025-01-01 |
| PRECLINICAL | evidence | "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. | Ozempic | — | 2025-01-01 |
| PRECLINICAL | evidence | Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations. | Rybelsus | — | 2025-01-01 |
| PRECLINICAL | evidence | Real-World Off-Label Use of Semaglutide for Weight Reduction: User Behavior, Effectiveness, and Satisfaction. | Ozempic | — | 2025-01-01 |
| PRECLINICAL | evidence | [Effects of semaglutide on mental health]. | semaglutida | Glycemic control | 2025-01-01 |
| PRECLINICAL | evidence | 'Ozempic, you're able': a festive parody song from the Nature Podcast. | Ozempic | — | 2024-12-24 |
| PRECLINICAL | evidence | In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists. | Ozempic | — | 2024-12-23 |
| PRECLINICAL | evidence | [Impact of Elon Musk's statements on the use of semaglutide in the Lazio Region: a time series analysis study.]. | Wegovy | Weight & fat loss | 2024-12-01 |
| PRECLINICAL | evidence | Investigating GLP-1 Injections: Potential Mitochondrial Dysfunction in Non-Diabetic Patients Presenting with Migraines and Hypoglycemia: A Case Report. | Ozempic | — | 2024-12-01 |
| PRECLINICAL | evidence | The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. | Ozempic | Glycemic control | 2024-12-01 |
| PRECLINICAL | evidence | Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide. | Rybelsus | — | 2024-12-01 |
| PRECLINICAL | evidence | Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. | Ozempic | — | 2024-11-07 |
| PRECLINICAL | evidence | A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point? | Ozempic | Weight & fat loss | 2024-11-01 |
| PRECLINICAL | evidence | Clinical Manifestations of Semaglutide Overdose: A Case Study. | Ozempic | Glycemic control | 2024-11-01 |
| PRECLINICAL | evidence | Population-Level Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Using Google Trends Statistics in a 12-Month Retrospective Analysis: An Infodemiology and Infoveillance Study. | Ozempic | — | 2024-10-01 |
| PRECLINICAL | evidence | Update on Perioperative Medication Management for the Hand Surgeon: A Focus on Diabetes, Weight Loss, Rheumatologic, and Antithrombotic Medications. | Ozempic | — | 2024-10-01 |
| PRECLINICAL | evidence | Late Facial Edema After Lip Filling With Hyaluronic Acid: Possible Association With the Use of Ozempic. | Ozempic | Skin appearance & aging | 2024-10-01 |
| PRECLINICAL | evidence | Daily Briefing: Drugs like Ozempic seem to help everything from Alzheimer's to infertility. But how? | Ozempic | — | 2024-09-25 |
| PRECLINICAL | evidence | Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface. | Ozempic | — | 2024-09-17 |
| PRECLINICAL | evidence | Prevalence Patterns of Body Contouring Procedures Among Injectable Glucagon-like Peptide-1 Receptor Agonist Users. | Ozempic | — | 2024-09-16 |
| PRECLINICAL | evidence | FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue. | Ozempic | — | 2024-09-01 |
| PRECLINICAL | evidence | Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Billion To $6.1 Billion. | Wegovy | Weight & fat loss | 2024-09-01 |
| PRECLINICAL | evidence | Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations. | Ozempic | — | 2024-09-01 |
| PRECLINICAL | evidence | The rise of "Ozempic Face": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. | Ozempic | — | 2024-09-01 |
| PRECLINICAL | evidence | Euglycemic Ketoacidosis From Semaglutide in a Patient Without Diabetes. | Wegovy | — | 2024-09-01 |
| PRECLINICAL | evidence | Trends in Glucagon-Like Peptide-1 Receptor Agonist Social Media Posts Using Artificial Intelligence. | Ozempic | — | 2024-09-01 |
| PRECLINICAL | evidence | Can Diabetes Drugs like Ozempic Tackle the Mental Health Crisis? | Ozempic | — | 2024-08-28 |
| PRECLINICAL | evidence | Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. | Ozempic | — | 2024-08-28 |
| PRECLINICAL | evidence | How do drugs such as Ozempic work for weight loss . . . and everything else? | Ozempic | Weight & fat loss | 2024-08-19 |
| PRECLINICAL | evidence | WHO Warns of Counterfeit Ozempic in the Global Supply Chain-Here's What to Know. | Ozempic | — | 2024-08-13 |
| PRECLINICAL | evidence | Table: GLP-1 and GIP/GLP-1 receptor agonists for chronic weight management. | Wegovy | Weight & fat loss | 2024-08-05 |
| PRECLINICAL | evidence | Table: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes. | Ozempic | Glycemic control | 2024-08-05 |
| PRECLINICAL | evidence | Wegovy: GP pilot scheme could be scrapped after failing to launch. | Wegovy | — | 2024-08-02 |
| PRECLINICAL | evidence | Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System. | Ozempic | — | 2024-08-01 |
| PRECLINICAL | evidence | Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. | Ozempic | — | 2024-08-01 |
| PRECLINICAL | evidence | Knowledge and Perception of Anti-obesity Medications Among Primary Healthcare Center Visitors in Jeddah, Saudi Arabia in 2024: An Analytical Cross-Sectional Study. | Ozempic | — | 2024-08-01 |
| PRECLINICAL | evidence | GLP-1R agonist therapy and vaccine response: Neglected implications. | Ozempic | — | 2024-08-01 |
| PRECLINICAL | evidence | The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review. | Ozempic | — | 2024-08-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making? | Ozempic | — | 2024-08-01 |
| PRECLINICAL | evidence | Plastic surgery amid a semaglutide epidemic: Direction for future studies and service implications. | Ozempic | Glycemic control | 2024-08-01 |